Page last updated: 2024-09-04

cox 189 and Allodynia

cox 189 has been researched along with Allodynia in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Castañeda-Hernández, G; Ortiz, MI; Salazar-Morales, UE; Trocóniz, IF; Vásquez-Bahena, DA1
Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM1
Bevan, S; Courade, JP; Dawson, J; Fox, A; Glatt, M; Gonzalez, I; Medhurst, S; Urban, L1
Berry, C; Dawson, J; Du, Z; Esser, R; Fox, A; Fujimoto, RA; Haston, W; Kimble, EF; Koehler, J; Marshall, PJ; Peppard, J; Quadros, E; Quintavalla, J; Toscano, K; Urban, L; van Duzer, J; Zhang, X; Zhou, S1

Other Studies

4 other study(ies) available for cox 189 and Allodynia

ArticleYear
Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.
    British journal of pharmacology, 2010, Volume: 159, Issue:1

    Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Carrageenan; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hyperalgesia; Inflammation Mediators; Models, Biological; Nonlinear Dynamics; Rats; Rats, Wistar; Time Factors

2010
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
    Pharmacological research, 2010, Volume: 62, Issue:5

    Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides

2010
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
    Pain, 2004, Volume: 107, Issue:1-2

    Topics: Analysis of Variance; Animals; Behavior, Animal; Bone Density; Bone Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; Hyperalgesia; Inflammation; Isoenzymes; Isoxazoles; Organic Chemicals; Pain; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Radiology; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tumor Cells, Cultured

2004
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    British journal of pharmacology, 2005, Volume: 144, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biological Availability; Blood Platelets; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Female; Fever; Fibroblasts; Humans; Hyperalgesia; Male; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rats, Wistar; Skin; Thromboxane B2

2005